Azitra, Inc.

Healthcare · Biotechnology · United States

Last price 0.7 USD (Oct 30, 2026, 9:41 AM EDT) · Market cap 4.24M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Ph...